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ABSTRACT
Protein Tyrosine Kinases (PTKs) are crucial enzymes which aid in cellular
signal transduction pathways as well as cell cycle regulation. This is accomplished by
phosphorylating downstream targets specifically on the hydroxyl group of tyrosine
residues. Equally important, extensive research has established a connection between
overexpression of PTKs and the development of certain cancers. One example of this
is seen in Chronic Myeloid Leukemia (CML) where a chromosomal translocation
occurs in patients which results in a hybrid, overexpressed BCR/Abl fusion PTK
ultimately leading to tumor formation. Thus, understanding PTKs along with what
substrates they act on is of utmost importance.
Along with understanding the structure and function of PTKs, identifying
which substrates they phosphorylate is crucial as well. There are several methods both
in vitro and in vivo which allow the study of PTK activity on their specific substrates.
Each method has some setbacks. Some methods can be time-consuming to set up and
use while other methods such as studying PTKs in mammalian cells can lack
consistency due to other factors in the cell that can act on these enzymes and alter
experimental data. A rapid and efficient system to allow characterization of
PTK/substrate relationships would be highly valuable. In the following research, a
bacterial system has been developed, optimized and tested which allows a researcher
to screen both wild type and mutant protein tyrosine kinases for their phosphorylation
activity on chosen substrates. In this screening model, PTKs Abl, Csk and Src and
their respective substrates (crk l, kdSrc) were used to demonstrate the effectiveness of
this method. Once demonstrated, chosen mutants of the above PTKs and substrates

were then tested to further validate this screening method. In both wild type and
mutant testing using this applied in vivo screening system, the expected
phosphorylation activity was demonstrated. This system can be used to identify
substrates for a known kinase, or kinase mutants with certain substrate specificity. It is
a useful platform for understanding the mechanisms of PTK substrate specificity.
Once this method was developed and proven, the protocol was optimized to allow
rapid colony screening of PTKs for substrate specificity. This method can be used to
screen mutant PTKs generated for the substrates they phosphorylate in a rapid,
effective manner in an effort to further understanding PTKs.
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INTRODUCTION

Protein Kinases and Signal transduction
There are a multitude of enzymes that occur in nature with a wide range of
functions. Some enzymes such as proteases help breakdown targeted proteins while
others like restriction enzymes recognize and cleave specific recognized regions of
DNA. Protein kinases function by transferring a phosphate group onto a target
substrate (phosphorylation) which allows for regulation of certain biochemical
processes such as cell cycle and signal transduction pathways.[1-3]
Several groups of protein kinases exist including but not limited to serine/threonine
kinases, histidine kinases and protein tyrosine kinases. The main difference between
these three groups of protein kinases is their method of action. Serine/threonine
kinases function by phosphorylating the hydroxyl group of either serine or threonine
side chains on their substrate. In contrast, histidine kinases first add a phosphate group
from ATP onto their own histidine residue and then usually transfer it to an aspartate
group on their substrate. Finally, protein tyrosine kinases transfer a phosphate group
from ATP to the hydroxyl of tyrosine residues on their substrates.[2]Regardless of
mode of action, stringent regulation of cell processes is achieved by the action of
protein kinases.

1

Oncogenes and Protein Kinases
Cancer research and treatment has changed gradually throughout the last
century. Initially, research focused on treating and preventing the proliferation of
cancerous cells. Treatment consisted of radiation and chemotherapy techniques that
have limited success and often cause patients to become immune to these therapies
and experience drug resistance. Overall, these treatments served as the most prevalent
mode of action to treat cancer patients. [4-6]
In contrast to treating the proliferation of tumor cells with the techniques listed above,
a new wave of cancer treatments focuses on controlling the activity and effects of the
underlying cause of a range of cancers, oncogenes. Oncogenes are the result of protooncogenes becoming mutated or overexpressed. Proto-oncogenes are genes that have
the capacity to induce cancer development through their protein and enzymatic
products, when they are either overexpressed or mutated.[5] The discovery of the first
retroviral oncogene, v-src, in 1911 was responsible for the importance placed on
understanding oncogenes and led to a shift in cancer therapy as well.[7, 8]

The discovery of the first oncogene v-src and its impact on cancer research
In 1911, Francis Peyton Rous, injected cell-free extract from a cancerous
chicken tumor into healthy chickens and observed that this was promoting cancer
development (sarcoma) in the chickens injected. Further research implicated the Rous
Sarcoma Virus (RSV) was the driving force behind the cancer generation in the
afflicted chickens.[7, 8] The Rous Sarcoma Virus genome contains three genes, gag, pol
2

and v-src and along with this, RSV has the capability to integrate its genes into the
host chromosome (chicken) and induce overexpression of these viral genes.[9]
Although overexpression of pol and gag is responsible for the replication of the virus,
overexpression of the viral v-src leads to uncontrolled mitosis of the host chicken cells
and ultimately tumor formation. The discovery of v-src was a breakthrough in science
and due to this amazing discovery in cancer research; Peyton Rous was awarded the
Nobel Prize in 1966.[10]
The work of Peyton Rous and research related to his discovery not only led to
a better understanding of the causative agent of cancer but also promoted research on a
new type of protein kinase group, protein tyrosine kinases. After the discovery of the
v-src oncogene, research on its function elucidated a new mechanism of protein
phosphorylation in which a phosphate group is attached directly to the hydroxyl group
on a tyrosine residue of the targeted substrate. Due to this, these protein kinases were
named protein tyrosine kinases (PTKs). The impact of the discovery of a new group of
enzymes and their ability to become oncogenic fueled researchers to discover, isolate
and study other PTKs.[2]
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Protein Tyrosine Kinases: Structure and Function
With the discovery of v-src’s function as a protein tyrosine kinase as well as its
oncogenic potential, this led to a booming increase in research driven toward
understanding the structure and functions of PTKs as well as the discovery of new
PTKs. This effort was applied in hopes that by understanding these unique enzymes
and their mode of action, cancer development linked to oncogenic PTKs could be
further understood, and therapeutic strategies can be developed.
Since the discovery of v-src, many other PTKs have been discovered including Abl,
Csk and Frk. These PTKs all have conserved regions as well as similar modes of
action, but their specific roles in a cell tend to vary.[2] Figure 1 shows the evolutionary
relationship between both receptor PTKs and nrPTKs present in nature.

Structure homology of PTKs: Receptor vs. Non-Receptor PTKs
When it comes to the protein tyrosine kinase family, there are generally two
types, receptor and non-receptor PTKs. The first type, receptor tyrosine kinases
(RTK) span the cellular membrane and bind extracellular ligands. There are 20 distinct
families of RTKs identified which can bind extracellular large and small ligands.[11]
Binding of extracellular ligands to RTKs generally causes dimerization of the receptor
and trans-phosphorylation of the kinase domain thereby activating it. This activated
kinase will then phosphorylate a downstream target and lead to amplification of the
signal. RTKs, such as EGFR, consist of three main domains including a
transmembrane
4

Figure 1. Evolutionary lineage of receptor and cytoplasmic PTKs.
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Figure 1. Evolutionary lineage of receptor and cytoplasmic PTKs. The phylogenetic
tree above depicts the evolutionary lineage of PTKs, both receptor and cytoplasmic.
The roots of the tree represent the most common ancestor of each species located at
the end of the branches. Figure adapted from Cell and Signaling Technology.[12]
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domain, extracellular ligand-binding domain, and finally an intracellular kinase
domain. In contrast, non-receptor PTKs (nrPTKS) such as Src and Abl are usually
found in the cytoplasm but can also be found within organelles. All nrPTKs contain a
conserved kinase domain similar to that of the RTKs. In addition, each nrPTK may
contain other regulatory domains. Most nrPTKs contain a conserved SH2 (Src
Homology 2) domain, SH3 (Src Homology 3) domain and sometimes a PH (Plektrin
Homology) domain.[3] In general, the conserved SH2 domain of nrPTKs is made up of
100 amino acids and tends to be located upstream of the catalytic domain of nrPTKs.[3,
12]

The conserved SH2 domain can bind to phosphorylated tyrosine containing

peptides and is also involved in localization to RTKs and other enzymes activated by
tyrosine phosphorylation.
Meanwhile, the conserved SH3 domain of nrPTKs is roughly 70 amino acids long and
is generally positioned upstream of the SH2 domain near the N-terminus. It has a
similar localization function as the SH2 domain and can regulate kinases and other
SH3-containing proteins. Finally in addition to the conserved SH3 and SH2 domains,
nrPTKs can have over 25 different accessory protein sequences either at the C or Nterminus of the protein sequence.[2, 11] These domains aid in kinase regulation or
function either intramolecularly or binding with other proteins that may be either
substrates or regulators. These accessory protein sequences can also aid in localization
and recruitment of targeted substrates

7

When comparing both RTKs and nrPTKs, crystallographic structures reveal generally
conserved kinase and catalytic domain structures (Figure 2). The kinase domains of
PTKs can be further divided into twelve sub-domains which fold together into a large
and small lobe. Subdomains I-IV comprise the smaller N-terminus lobe and play a role
in Mg/ATP binding. Meanwhile subdomains VI-XI make up the larger C-terminal
lobe and aid in peptide/substrate recognition and phosphotransfer. Finally, the two
separate lobes are linked by subdomain V.

PTK enzyme catalysis
Enzyme catalysis is similar among PTKs as well. The catalytic domains of
PTKs consist of two lobes which come together to form the catalytic cleft. The Nterminal residues form the ATP binding lobe while the C-terminal residues form the
substrate binding lobe. Once a substrate and ATP bind to their respective binding sites,
the γ phosphate and the substrate hydroxyl group are positioned close to each other in
the catalytic cleft. Next, catalysis will occur facilitating the transfer of the γ phosphate
group from ATP onto the specific tyrosine residue of the substrate.[2] It has also been
noted that catalytic efficiency is enhanced in the presence of divalent metal cations
such as Mn2+ and Mg2+.[13] The amino acids present around the targeted tyrosine
residue of the incoming substrate play a huge role in increasing binding affinity and
catalytic efficiency. Although this is true, there is no consensus on which surrounding
specific amino acid residues help determine catalytic efficiency.

8

Figure 2. Comparison of structural domains among several nr-PTKs.
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Figure 2. Comparison of structural domains among several nr-PTKs. The relative
conserved and non-conserved structural domains between several nr-PTKs are shown
and compared in the figure above. Figure adapted from Cell Biology.[15]
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Amino acids outside the catalytic cleft can also play a huge role in increasing the
efficiency of catalysis within PTKs. An example of this is when inactivation of Src is
carried out by Csk on a specific C-terminal tyrosine 527. A specific stretch of amino
acids on Csk’s peptide binding lobe termed RSRGRS is crucial for Csk inactivation of
Src. Without this region, inactivation of Src by Csk does not occur.[14] Despite similar
modes of catalytic action, PTKs still achieve a high level of substrate specificity.
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Model Protein Tyrosine Kinases
With the wide variety of nrPTKs that exist, it is a challenge for researchers to
understand how cell signaling through PTKs is achieved. Although the catalytic
domains and catalytic mode of action is generally conserved, they still manage to
achieve a high level of substrate specificity. An example of this is Src PTK which
demonstrates substrate specificity for its auto-phosphorylation site (Tyr416), but
cannot phosphorylate its inactivation site (Tyr527), which is targeted by another PTK,
Csk.[3, 12, 15] Based on this, researched have grouped nrPTKs into specific families
which share similarities both structurally as well as the regulatory features they
possess. Several of these model kinase families include the Src family kinases (SFKs),
Csk family kinases, Abl family kinases (AFKs), Frk family kinases and finally the Tec
family kinases. By grouping nrPTKs into subfamilies, it can provide an overall
understanding of how signal transduction is achieved by these different nrPTKs. The
three model PTK families Src, Csk and Abl that are relevant to the applied research
will be discussed below.

Src family kinases (SFKs)
Being the first PTK discovered and having oncogenic potential, much is
known about Src and related SFKs such as FYN and Yes. The SFK contains 9
members and tend to regulate important cell processes such as cell growth, migration,
differentiation, and survival throughout various tissues in the body.[2] They directly act
on growth factors and play a huge role in growth factor signaling pathways. Although
12

each SFK plays important roles in normal cell development and function, elevated
levels of SFKs have been associated with oncogenesis in humans, specifically in colon
cancers and other cancers such as lymphoma and melanoma.[2]
SFKs have a structure containing an SH3 domain, an SH2 domain, a kinase domain,
an N-terminal variable site which can be modified by myristoylation or palmitoylation
and finally a flexible tyrosine containing C-terminal tail. The SH2 domain plays a role
in binding phosphotyrosine-containing peptide sequences while the SH3 domain has
been shown to bind type II polyproline helix ligands. Meanwhile, the N-terminal
variable region plays a role in membrane recruitment. Finally, the highly conserved Cterminal tail serves as a regulator of SFKs through phosphorylation or dephosphorylation of the tyrosine located on the tail.[2, 12, 15]
Although SFKs have been shown to be oncogenic, there has to be strict regulation of
SFKs to prevent this from always occurring inside the cell. This is achieved by a
stringent regulation on two important residues contained in SFKs. The first residue,
tyrosine 416, is the site of autophosphorylation of SFKs, which when phosphorylated
activates the enzyme. This activating tyrosine is present in the autophosphorylation
loop, a region highly conserved in amino acid sequence(RLIEDNEYTARQGAK)
among SFKs and closely related members.[3] In contrast, phosphorylation by Csk on
tyrosine residue 527 on the C-terminal flexible tail of Src inactivates the enzyme and
renders it inactive. When phosphorylated, the phosphorylated tyrosine residue 527
interacts with Src’s SH2 domain and allows the SH3 domain and linker region to
come together keeping the enzyme in an inactivated state.[2, 3, 12, 14] Because Src is a
substrate for both Csk and Src, but on different tyrosine residues, it is an ideal
13

substrate for testing the substrate specificity for Csk and Src. The structural
organization and regulation of Src is shown below in Figure 3.

Csk family kinases(CFKs)
The Csk family kinases are made up of two members, Csk (C-terminal Src
Kinase) and Chk (Csk homologous Kinase). Both play a role in negatively regulating
members of the Src family. Two pieces of evidence indicates that Csk and Chk belong
to the same family. First, both members share a similar structural organization
containing an SH3, SH2 and the SH1 domain from N-terminus to C-terminus order.
Second, both members lack an auto-phosphorylation site, an SH4 myristoylation
signal and regulatory phosphorylation sites common to their closest PTK family,
SFKs.[1, 12, 14] Contrary to SFKs though, CFKs are considered tumor suppressors rather
than having oncogenic potential. The main evidence of this was provided by
performing mouse knockout studies on Csk where deletion of the Csk gene leads to
early-stage embryonic lethality and several neural tube defects. Without Csk present,
SFKs become consistently active and have devastating consequences. Also, Csk/Src
double knockout mice develop to near parturition and show normal development
which strongly suggests that CFKs are a crucial regulator and necessary for
moderating SFKs in the cell.[12]
Structurally, Csk family kinases share a 40% sequence identity when compared to Src.
They share a conserved SH2, SH3 and catalytic domain with Src but significant
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differences do exist. Missing from their structure is an N-terminal lipid anchoring
domain, an activation loop tyrosine and finally a C-terminal tyrosine-containing tail.

15

Figure 3. The structural organization and regulation of Src PTKs.
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Figure 3. The structural organization and regulation of Src PTKs. The following
figure depicts the events that lead to activation and inactivation of Src PTKs as well as
their structural organization. Initially, phosphorylation at tyrosine residue 527
maintains the enzyme in an inactive site. Interaction with the SH2 domain keeps this
enzyme in a closed conformation. Full activation is achieved when specific ligands
bind to Src’s SH2 or SH3 domains resulting in de-phosphorylation at tyrosine residue
527, thereby promoting formation of Src’s active conformation. This is followed by
auto-phosphorylation on tyrosine residue 416 of Src, leading to the full activation state
of the enzyme. Figure adapted from the International Journal of Biological Sciences.[3]
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This suggested to researchers that Csk was a distant relative of Src with a different
mode of regulation.[3, 12]
It has been established that CFKs have limited and highly specific substrate
targets, usually of the SFK. Due to such a high level of substrate specificity, this lends
support as to why Csk was one of the first full-length protein tyrosine kinase to be
overproduced efficiently in E.coli with the addition of chaperonins GroES and GroEL.
By having a stringent level of substrates it targets, Csk proved to be less toxic when
introduced to foreign hosts such as E.coli. Due to the ability to overproduce the Csk
enzyme with this novel strategy, it has been widely studied and serves as a model
PTK. In contrast, efforts to purify Chk enzyme have been unsuccessful in the past
making it hard to study as well.[1, 3, 12] Csk’s structure and regulation of Src PTKs are
shown below in Figure 4.

Abl family kinases(AFKs)
The Abl family of non-receptor tyrosine kinases (AFKs) includes both
c-Abl (cellular Abl) encoded by ABL1 and its relative Arg (Abelson-Related Gene)
encoded by ABL2. ABL genes are found in all metazoans, suggesting that both their
structure and function were fixed early in tyrosine kinase evolution. AFKs function in
such processes as cell growth, cell survival and DNA repair.[16, 17]
Structurally, both members of AFK share conserved N-termini containing an Nterminal cap, myristoylation site, SH3 and SH2 domain, and similar kinase domains.

18

Figure 4. Csk structure and activity on Src substrate.
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Figure 4. Csk structure and activity on Src substrate. Domain organization of Csk and
SFKs is shown in the figure above. Csk inactivates SFKs through phosphorylation on
tyrosine residue 527. An amino acid alignment of the activation loop of Csk and SFKs
is also depicted above. Figure adapted from International Journal of Biological
Sciences.[3]
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In contrast, the C-terminus is quite different in that c-Abl contains nuclear localization
and export signals as well as a DNA binding domain that Arg does not possess. Both
members do however contain an F-actin binding domain located at their C-termini.[17,
18]

AFKs have been shown to be phosphorylated by members of the SFKs and have been
shown to possess autoinhibitory mechanisms as well. These include a myristoyl group
that can bind to the surface pocket in AFKs kinase domain and contribute to an
autoinhibitory fold. Along with this, AFKs contain an amino-terminal cap which can
stabilize the inactive conformation of these enzymes using specific surface
interactions. Further experiments have demonstrated that disruption of these
autoinhibitory mechanisms result in an increase in kinase activity of AFKs.[16, 18]
Another similarity to SFKs is that AFKs are proto-oncogenic and can become
oncogenic due to certain mutations or overexpression events. An example of this
occurs in patients with Chronic Myeloid Leukemia where a chromosomal
translocation occurs between the Abl gene on chromosome 9 and the breakpoint
cluster gene on chromosome 22. This fusion generates a Chimeric Chromosome called
the Philadelphia chromosome (Figure 5).[16, 19] The result of this is a 210 kDa chimeric
PTK called BCR/Abl which is constitutively expressed. Due to overexpression of the
BCR/Abl gene, several crucial consequences occur. First, the Abl kinase domain
becomes much more active thereby phosphorylating a variety of different substrate
proteins. Second, BCR/Abl PTK has critical domains and sequence motifs which
causes activation of downstream targets. Lastly, the fusion protein becomes strongly

21

Figure 5. The occurrence of the Philadelphia Chromosome in patients with
Chronic Myeloid Leukemia (CML).

]
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Figure 5. The occurrence of the Philadelphia Chromosome in patients with Chronic
Myeloid Leukemia (CML). In CML, a chromosomal translocation occurs between the
Abl gene on chromosomes 9 and the breakpoint cluster gene (BCR) on chromosome
22. This translocation results in formation of a BCR/Abl fusion chromosome termed
the Philadelphia Chromosome. This leads to production of an un-controlled and
overexpressed BCR/Abl fusion PTK and development of CML. Figure adapted from
the Chronic Myelogenous Society of Canada. [22]

23

auto-phosphorylated causing it’s catalytic activity to increase heavily. Due to these
three consequences, several cellular effects occur including uncontrolled cell
proliferation, reduced DNA repair, and ultimately Chronic Myeloid Leukemia.[16, 19]
Although many signaling pathways are activated by BCR/Abl, only a few proteins
appear to be necessary for BCR-Abl-dependent transformation. These include the
proteins Gab2, Myc, CrkL and STAT5. Out of these 4, CrkL is among the most
preferred substrates of both wild type Abl and BCR/Abl and its binding to BCR/Abl
PTK is necessary for oncogenic transformation to occur in CML patients.[16, 20] Being
a substrate for both Abl and BCR/Abl, crk-l has become heavily studied. It functions
in numerous biological processes including cell adhesion and migration, cell
proliferation, apoptosis, and regulation of gene expression.

Studying PTKs and drawbacks of developed methods
Although much is known about PTKs, there are several drawbacks to the
methods designed to study these intricate enzymes. In vivo methods such as studying
PTKs in mammalian cells can produce complex and hard to interpret results. The main
reason for this is that in a mammalian cell, there are many other factors that can play a
role in mediating or altering the activity of the PTK being studied. One example of
this occurs when researchers attempt to study inactivation of the SFK and FGFR
families by reactive oxygen species (ROS) in vivo. Although studies showed that these
PTKs might have been inactivated by the presence of ROS, they were unable to
directly correlate it to the addition of ROS. This is due to the possibility of other
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regulatory factors such as members of CFK inactivating these PTKs rather than the
ROS being the direct cause of inactivation.[21] A similar problem occurs generally
when studying most PTKs due to these other regulatory factors being present inside
the cell and influencing the study of these enzymes by their regulatory actions.
Along with in vivo methods to study PTKs, in vitro methods such as radioactive
kinase assays have their drawbacks as well. Radioactive kinase assays consist of using
radioactive ATP along with both purified enzyme (PTK) and substrate in an intricate
time-based reaction.[14] The drawbacks to this analysis method is that first, the
researcher must be able to purify both PTK and substrate to a very high purification
level; otherwise the experiment conducted will not be valid. Purification methods do
work for many PTKs but some PTKs fail to express and purify correctly such as seen
in attempts to purify Chk enzyme.[1] Also, some PTKs and substrates do purify but
can contain contaminants when purified. Lastly, radioactive kinase assays require the
use of radioactivity and its use has strict regulations and can be difficult to work with.

25

Focus of this thesis
The experimental data, results and discussion pertinent to this work focuses on
two related projects, both of which have a similar goal of developing and optimizing
systems to understand and rapidly screen PTKs for substrate specificity. The first
project involves developing and optimizing an in vivo bacterial system which allows a
researcher to rapidly screen PTKs for substrate specificity. The second project focuses
on a colony screening method which allows for the screening of mutant PTKs in a
rapid, effective manner. Both projects are aimed at allowing researchers to efficiently
study PTKs and their substrates in an effort to further understand their function and
roles, specifically in oncogenesis.

Developing a rapid, efficient bacterial system to analyze substrate specificity in PTKs
In an effort to overcome drawbacks experienced by researchers in analyzing
PTKs as well as the substrates they target, a novel, bacterial system has been
developed and optimized which allows for rapid analysis of substrate specificity in
PTKs. The system developed consists of co-expressing both PTK and substrate to be
analyzed in a bacterial host and following an optimized, rapid protocol which has been
shown to produce expected substrate specificity when tested. By using this developed
system, researchers now have another method to study PTKs with few of the
drawbacks that other methods tend to present such as outside factors acting on PTKs
and purification problems as seen in radioactive kinase assays.
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Screening of generated PTK mutants for substrate specificity using a rapid colony
screening method
In an effort to understand PTKs function and role, PTK mutants have been
generated and studied using similar techniques as when studying non-mutated PTKs.
Regardless of whether mutant or non-mutant, there are several problems that arise.
First, the generation of mutant PTKs is time-consuming and requires prior-analysis to
verify the mutations being made are relevant. Second, once established, the methods
used to analyze these mutants suffer similar drawbacks as when studying wild type
PTKs whether in vivo and in vitro. Recent research focuses on rapid generation of
mutant PTKs with such techniques as DNA shuffling.[22, 23] Once established and
proven reliable, there must be a system developed to rapidly screen these PTK mutants
for their substrate specificity, which is the current goal of this study. To do this, model
PTKs Abl, Csk and Src and their preferred substrates, either crk-l or kdSrc, will be
used to verify this screening method. By using this optimized system to test mutant
PTKs, one can rapidly screen hundreds of mutants, in a small amount of time.
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Abstract:
Protein tyrosine kinases are important enzymes whose phosphorylation activity
on tyrosine residues of their substrates helps dictate cellular signal transduction as well
as vital cell activities such as cell cycle regulation. These enzymes demonstrate
stringent regulation on signal transduction by achieving a high level of substrate
specificity. Recent research linking PTKs to certain cancers has made understanding
their substrate specificity of utmost concern.
There are several in vivo and in vitro methods to analyze substrate specificity of PTKs
but they tend to be time-consuming and can produce unreliable results. In vivo
methods in mammalians are important but generally involve too many outside factors
and influences when trying to analyze substrate specificity of a certain PTK. In
contrast, in vitro methods such as radioactive kinase assays do produce accurate
results but require the purification of substrate and enzyme as well as using
radioactivity, a general hazard.
The following research presents a rapid and efficient bacterial system for analyzing
substrate specificity of PTKs. The model PTKs and substrates to be tested are cloned
into specific plasmids and co-expressed in E.coli. Following this, western blot and
specific antibodies are used to screen the model PTKs for substrate specificity. The
model PTKs Abl, Csk, Src and their preferred substrates, either crk-l or kdSrc, were
used to verify the effectiveness of the proposed system. By producing the expected
substrate specificity using these model PTKs, the accuracy of the system is also
demonstrated.
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Once the above system is proven effective, it will be optimized to allow for rapid
screening of mutant PTKs using a colony screening method. Currently, one approach
used to analyze PTKs and their structure is to perform site-directed mutagenesis on
specific chosen sites on PTKs and analyze the effect on both structure and
phosphorylation activity. Although beneficial, this process can be time-consuming and
the mutations made do not always produce important results when tested. Regardless,
newer approaches implemented by some researchers allow for rapid generation of
mutants PTKs using such techniques as DNA shuffling. Along with the capacity to
rapidly generate mutants, there must be a way to rapidly screen these mutant PTKs for
substrate specificity. A colony screening method has been developed and optimized
using model PTKs Abl, Csk and Src and their preferred substrates. This developed
screening method can be used to rapidly screen mutant PTKs generated by the novel,
fast techniques available currently.

Keywords: protein tyrosine kinase; substrate specificity; in vivo bacterial system;
Abl; Csk; Src; crk-l; kdSrc; colony screening.
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Introduction:
Protein tyrosine kinases are important enzymes in mammalian signal
transduction pathways as well as many other important cellular processes such as cell
cycle regulation. They phosphorylate specific substrates on their tyrosine residues
using a phosphate group derived from ATP.[1-3] By doing this, these enzymes regulate
specific cellular activities and cell function. Although generally sharing several
conserved structures, PTKs still manage to exhibit very specific substrate specificity
even when comparing homologous PTKs such as Src and Csk.[1-3]
Recent breakthrough research has linked several PTKs to the development of certain
cancers. An example of this is in Chronic Myeloid Leukemia (CML) where a
chromosomal translocation produces a mutated, overexpressed BCR/Abl PTK which
leads to unregulated cell proliferation and subsequent tumor formation in patients with
CML.[4] In contrast, PTKs such as Csk have been shown to be tumor suppressors,
inactivating PTKs of the Src family.[3] Regardless of whether oncogenic or tumor
suppressing, this recent research has placed utmost importance on understanding
substrate specificity of these enzymes. The hopes are that by discovering and
understanding the targets of PTKs, this information can be used to develop drugs that
target PTKs or their substrates and regulate the effects of these mutated or
overexpressed enzymes in afflicted cancer patients.
There are several developed methods to test substrate specificity of PTKs but
regardless of the methods used, all remain time-consuming and can produce erroneous
results. Using in vivo mammalian cells to analyze substrate specificity of PTKs can be
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performed, but the results can be misleading due to the amount of other proteins and
enzymes in a cell that can alter substrate specificity of PTKs.[5] Relevant to this, in
vitro methods such as radioactive kinase assays require the purification of both PTKs
and substrates and involve using radioactive compounds.[5,6] Regardless whether in
vivo or in vitro, both ways tend to present a myriad of problems to a researcher.
In the following research, we sought to develop and optimize a bacterial
system which can be used to analyze substrate specificity of PTKs in a rapid, accurate
manner. Using this developed system, three specific model nrPTKs (Abl, Csk and Src)
were expressed in combination with their preferred substrates, either crk-l or kdSrc, in
an effort to achieve the predicted substrate specificity demonstrated by these protein
tyrosine kinases. Once predicted substrate specificity by these PTKs was verified, both
mutant PTKs and substrates were also tested to further validate the system developed.
By demonstrating proper substrate specificity using both wild-type and mutant PTKs
with their substrates, a new in vivo method for analyzing substrate specificity of
respective PTKs has been developed which is both rapid and accurate. Once this
method was established, it was optimized in an effort to develop a colony screening
method that can detect substrate specificity of rapidly generated mutant PTKs
contained in colonies on a bacterial plate. Model PTK Abl, Csk and Src and their
preferred substrates were once again used to demonstrate the effectiveness of this
rapid, novel colony screening method.
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Materials and Methods:
Reagents and Chemicals
Consumables and culture media, or media components were purchased from
Fischer Scientific. The PY20 anti-phosphotyrosine antibody was purchased from
Santa Cruz Laboratories. The P-Src (Y527), P-Src (Y416) and Anti-Rabbit IgG was
purchased from Cell Signaling Technology. The p-Tyr antibody(PY20) antibody was
purchased from Santa Cruz laboratories. The Phospho-Crkl (207) antibody was
purchased from Abcam and the anti-mouse IgG secondary antibody from SigmaAldrich. All other chemical reagents used were purchased from Sigma-Aldrich.

Cloning of model PTKs and Substrates into selected plasmids
After optimization by Yixin Cui, it was shown that expression of selected PTK
coding regions of wild-type Abl, Csk(full-length), Src(aa 83-533) and mutants into
low copy number plasmid pCDF-1b was shown to work best in achieving proper
substrate specificity in this system. The substrates tested kdSrc and its mutants were
previously cloned into low copy number plasmid pRSET-A. [5,6] Substrate crk-l was
previously cloned into pGEX-4t-1.[4] To clone the selected coding regions of the PTKs
Abl, Csk, Src and mutants into pCDF-1b, a general sub-cloning procedure was
followed. Generally, the plasmids that contained the selected PTK coding regions and
the pCDF-1b plasmids to be cloned into were digested in 50 µl Eppendorf tubes with
specific restriction enzymes at 37° Celsius for 1 hour. The digestion products were
loaded onto a 1% agarose DNA gel and the proper-sized bands gel-extracted using
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Qiagen’s QIAquick gel extraction kit and quantified with Thermo-Scientific’s
Nanodrop 8000. Once quantified, specific quantities of both digested insert and vector
were used to set up calculated insert to vector ratios and these were ligated overnight
@ 16°C. Next, these ligation products were transformed into electro-competent E.coli
Bl21-Gold(DE3) cells using electroporation(2mm cuvettes) and plated on LB plates
containing appropriate antibiotics and incubated overnight in a 37°C non-shaking
incubator. The following day, colony-PCR was performed on the colonies produced
using a combination of primers specific for pCDF-1b plasmid (pCDF-1b +) and the
insert cloned (ex. Src Y454A -). Restriction enzyme digest analysis was also
performed using the same restriction enzymes initially used to clone in the insert to
further verify correct sub-cloning of desired insert into pCDF-1b. Finally, the newly
made insert-containing plasmid products were sent for sequencing to the University of
Rhode Island Genomics and Sequencing Center and subsequently verified by
sequence analysis.

Co-expression of PTK-containing and substrate-containing plasmids in E.coli BL21Gold(DE3)
Through cloning as described above, the PTK-containing plasmids were
already present in the strain of choice, E.coli BL21-Gold(DE3) and these stocks were
then separately made electro-competent using a general high-efficiency electrocompetent cell protocol. The substrate-containing plasmids, either pRSET-A or
pGEX-4t-1, were isolated from previously made stock cultures using Qiagen’s
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miniprep kit, and transformed into the appropriate strains using electroporation in
2mm cuvettes. The transformed products were recovered in 500µl of LB media for 1
hour in a 37°C shaking incubator(225 rpm) and this recovery product was then plated
on LB plates with appropriate antibiotics added. The following day, the transformant
colonies were tested for presence of both PTK and substrate-containing plasmids using
colony PCR with primers specific for each plasmid and insert. Table 1 indicates
exactly which PTK/Substrate combinations were made to be tested using the
developed screening system. Table 2 indicates the PTK/Substrate combinations tested
using the colony screening method. Once tested, the expression and activity of the
PTK/substrate strains were verified by performing a western blot using P-tyr
antibody(PY20,) which detects phospho-tyrosine containing proteins.
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TABLE 1. PTK and substrate combinations generated for testing with developed
method.
PTK-containing plasmid

Co-expressed

Substrate-containing plasmids

with*
1.) pGEX-4t-1-crk-l
+

2.) pRSET-A-kdSrc(wt)

pCDF-1b-Abl

3.) pRSET-A-kdSrc-Y416F
4.) pRSET-A-kdSrcY527F
1.) pGEX-4t-1-crk-l

pCDF-1b-Csk(wt)

+

2.) pRSET-A-kdSrc(wt)
3.) pRSET-A-kdSrc-Y416F
4.) pRSET-A-kdSrcY527F
1.) pGEX-4t-1-crk-l

pCDF-1b-Csk-R281A + R283A

+

2.) pRSET-A-kdSrc(wt)
3.) pRSET-A-kdSrc-Y416F
4.) pRSET-A-kdSrcY527F
1.) pGEX-4t-1-crk-l

pCDF-1b-Src(wt)

+

2.) pRSET-A-kdSrc(wt)
3.) pRSET-A-kdSrc-Y416F
4.) pRSET-A-kdSrcY527F
1.) pGEX-4t-1-crk-l

pCDF-1b-Src-RSRGRS + Y458F

+

2.) pRSET-A-kdSrc(wt)
3.) pRSET-A-kdSrc-Y416F
4.) pRSET-A-kdSrcY527F

*Escherichia coli BL21(DE3) was used as the host strain in all co-expressions.
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TABLE 2. PTK and substrate co-expressions used in developed colony screening
method.

PTK-Containing Plasmid

Co-expressed

Substrate-containing Plasmid

with*
1.) pGEX-4t-1-crkl
pCDF-1b-Abl

+

2.) pRSET-A-kdSrc
1.) pGEX-4t-1-crkl

pCDF-1b-Csk

+

2.)pRSET-A-kdSrc
1.)pGEX-4t-1-crkl

pCDF-1b-Src

+

2.)pRSET-A-kdSrc

*Escherichia coli BL21(DE3) was used as the host strain in all co-expressions.
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Preparation of samples to be tested
Once the appropriate strains were made, each PTK/substrate combination
strain to be tested was grown in 5 ml of LB media with appropriate antibiotics added
for approximately 13 hours in a 37°C shaking incubator(225 rpm) until an OD600 value
between .7 and 1.4 was reached. To normalize the amount of cells in each sample to
be tested, an equation (200µl/OD600 value= amount aliquoted) was used. Once the
appropriate amount of each culture was aliquoted into Eppendorf tubes, samples were
spun at 13,000 rpm for 5 minutes in a mini-spin Eppendorf centrifuge then
resuspended in 25µl of 1X SDS sample buffer with β-Mercaptoethanol and heated in a
95°C heating block for 10 minutes. After heating, samples were once again spun at
13,000 rpm for 5 minutes and approximately 9µl of each sample to be tested was
loaded appropriately into Biorad 15 well any-kD protein gel and run for 1 hour at 100
volts in an SDS-PAGE buffer system. Once complete, the gel produced was used for
western blotting purposes as described below. Duplicate gels were also produced and
subsequently Coomassie stained for 30 minutes to vefiry the quantitation of samples.
Following de-staining and equilibration in water, gels were analyzed with the Bio-Rad
GelDoc system.

Western Blotting of Samples and Exposure
For western analysis, samples were first subjected to SDS-PAGE as described
above. The resolved protein gels produced were incubated in transfer buffer along
with the appropriate filter paper and membranes used. The protein gels were then
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blotted to a 0.45 µm nitrocellulose membrane at 15 volts for 15 minutes using BioRad’s semi-dry transfer apparatus. Once complete, the membranes are then quickly
rinsed in 20 ml TBST buffer for 2 minutes and blocked in 20ml, 5% non-fat milk for
approximately 1 hour with gentle shaking. Upon completion of blocking, membranes
were washed 3 times for 3 minutes with TBST buffer and then incubated in the
appropriate 1° antibody concentration in TBST for 1 hour at room temperature with
gentle agitation. After 1 hour incubation with 1° antibody, the membranes were rinsed
3 times for 5 minutes in TBST buffer. After washing, the membranes were then
incubated in the appropriate secondary antibody diluted in 5% non-fat milk for 1 hour
at room temperature with gentle shaking. Subsequently, the membranes are then
washed 3 times for 5 minutes each with TBST buffer. Membranes are then dried and
incubated for 1 minute in Bio-Rad’s clarity reagent (250 µl of each solution A,B).
After incubation in the clarity reagent, the membranes are placed in between
laminating sheets and exposed for multiple time points using high resolution chemiblot protocol in Bio-Rad’s Universal Hood II GelDoc imager system.

Optimized colony screening sample preparation
To prepare samples, the strains to be tested are used to inoculate 5 ml of LB
broth contained in a 15 ml culturing tube with appropriate antibiotics added. These
culture tubes are then grown for approximately 13 h (till logarithmic phase) in a 37°
shaking incubator. After approximately 13 h of growth, the OD600 value is measured
and the cultures are then induced with 0.45 µm IPTG for 1 hour at room temperature
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with gentle shaking. After 1 hour of induction, approximately 0.5µl of each culture to
be tested is pipetted directly onto a sterile 0.45µm nitrocellulose membrane. The
number of samples that can be tested with this method is only limited to size and
spacing that can be accomplished on the membrane to be used. For optimization
purposes, approximately 5, 0.5µl samples of each PTK/Substrate combination to be
tested was pipetted from left to right onto the membrane with at least ½ inch
separation between samples. This spacing ensures that the signals produced by each
sample do not counteract with signals from other samples after western blot. Once the
membrane is prepared with samples, the membrane is then placed in a petri dish with
approximately 15ml of 10% SDS buffer added and then placed inside a 95°C oven for
10 minutes to lyse cells and release proteins. After heating of membrane, membrane is
quickly rinsed in TBST and followed up by an optimized western blot protocol
specific for this developed method.

Optimized Colony Screening Western Blot protocol
Upon quickly rinsing membrane with 15 ml TBST buffer, membrane is
blocked in 5% non-fat milk with gentle shaking for 30 minutes. After blocking,
membrane is washed 3 times (2mins/wash) with 15ml TBST buffer by gentle
agitation. Next, the membrane is incubated for 1 hour at room temperature in the
appropriate primary antibody concentration diluted in TBST buffer with shaking.
After incubation with the primary antibody, membrane is washed 3 times
(3mins/wash) with 15 ml TBST buffer per wash. Following, membrane is incubated in
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the appropriate concentration of secondary antibody diluted in 5% non-fat milk for 1
hour at room temperature. Next, membrane is washed 3 times (3mins/wash) in TBST
buffer than membrane is dried and exposed to BioRad’s clarity reagent for 2 minutes.
After incubation in the clarity reagent, the membranes are placed in between
laminating sheets and exposed for multiple time points using high resolution chemiblot protocol in Bio-Rad’s GelDoc imager system.
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Results and Discussion:
Demonstrating substrate specificity of model kinases Abl, Csk and Src
To demonstrate the effectiveness of the developed and optimized screening
method, we tested the substrate specificity of model PTKs Abl, Csk and Src toward
their known substrates. First, Abl should show a high level of phosphorylation of
substrate crk-l on tyrosine residue 207 when compared to both Csk and Src which
have low phosphorylation activity on this substrate. Second, Src should demonstrate
greater substrate specificity for its preferred substrate kdSrc on tyrosine residue 416 in
comparison to both Abl and Csk respectively. Finally, Csk should demonstrate a high
level of substrate specificity on tyrosine residue 527 of kdSrc, when compared to both
Abl and Src.
The first substrate tested using the developed screening method in combination
with the model PTKs above was crk-l, Abl’s preferred substrate. Abl demonstrated
high substrate specificity toward crk-l on tyrosine residue 207 in comparison to both
Csk and Src as expected. The result of this can be seen in Figure 1.
The next substrate tested, kdSrc, is phosphorylated by both Csk and Src but on
different tyrosine residues (Tyr 416(Src), Tyr 527(Csk)). This modified kdSrc
substrate has a lysine to methionine mutation in its ATP binding region which heavily
reduces its autophosphorylation ability. The first residue, tyrosine 416, is the preferred
auto-phosphorylation site of Src and proper substrate specificity should be
demonstrated when compared to Abl and Csk which both show minimal
phosphorylation activity on this residue. Once again, the expected high
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60 kD crk-l
(tyr207)

No Induction (1-4)

PTK

N/A

Abl

Csk

1 hour induction (5-8)

N/A
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Abl

Csk

Src

Figure 1. Abl, Csk and Src phosphorylation of substrate crk-l at tyrosine residue 207.
All samples tested contained an identical substrate, crk-l. Lanes 1 and 5 serve as
control lane samples containing substrate crk-l only with no PTK co-expressed. Lanes
2- 4 represent samples of Abl, Csk and Src separately co-expressed with substrate crkl before induction with IPTG. Lanes 6-8 represent samples 2-4 after 1 h of induction
with 0.4mM IPTG. The approximate size of the crk-l band is indicated by the arrow.
Antibodies used to perform blot were 1° Phospho-crk-l (tyr207) at a 1:50,000
concentration and 2° anti-mouse IgG HRP-linked antibody at a 1:15,000
concentration. All samples were produced and tested according to the developed
screening method protocol as described in materials and methods section.
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phosphorylation activity of Src toward this residue was observed in comparison to Abl
and Csk which showed minimal activity as shown by the western blot in Figure 2
below.
Finally, Csk must demonstrate high substrate specificity toward kdSrc on tyrosine
residue 527 when compared to Abl and Src. As expected, substrate specificity of Csk
toward kdSrc on tyrosine residue 527 was in fact observed in comparison to both Abl
and Src as shown in Figure 3.
Overall, demonstrating the expected substrate specificity of the three chosen
model PTKs using the developed screening method relied heavily on optimization of
the system. Initially, each strain tested was induced for 1 hour with 0.4mM IPTG upon
reaching a logarithmic phase OD600 value and cell lysates were produced at both 0
hour and 1 hour induction time periods as in Figure 1 above. Initially, this worked
great when testing substrate specificity of the PTKs tested toward crk-l substrate. In
contrast, when testing substrate specificity of the various chosen PTKs toward kdSrc,
it was seen that 1 hour induction samples tend to produce results not consistent with
the expected substrate specificity of the PTKs tested. In detail, phosphorylation of the
kdSrc substrate by both Csk and Src was becoming too saturated in samples taken
after 1 hour induction with 0.4mM IPTG and not producing the expected difference in
substrate specificity. Due to this, future cell lysate samples used in the developed
screening method were not induced and taken at the appropriate OD600 value. This led
to the conclusion that leaky-expression of both PTK and substrate-containing
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Src

Figure 2. Abl, Csk and Src phosphorylation of substrate kdSrc at tyrosine residue 416.
All samples tested contained an identical substrate, kdSrc. Lane 1 serves as a control
and contains substrate kdSrc only with no PTK co-expression. Lanes 2-4 are samples
tested containing substrate kdSrc co-expressed individually with Abl, Csk or Src PTK.
The approximate kdSrc band is indicated by the arrow. Antibodies used to perform
blot were 1° Phospho-Src (Y416) at a 1:5,000 and 2° anti-rabbit IgG at a 1:10,000. All
samples were produced and tested according to the developed screening method
protocol as described in materials and methods section.
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Figure 3. Abl, Csk and Src phosphorylation of substrate kdSrc at tyrosine residue
527. All samples tested contained an identical substrate, kdSrc. Lane 1 serves as a
control and contains substrate kdSrc only with no PTK co-expression. Lanes 2-4 are
samples tested containing substrate kdSrc in combination separately with the three
PTKs Abl, Csk and Src. The approximate size of the kdSrc band is indicated by arrow.
Antibodies used to perform blot were 1° Phospho-Src (Y527) at a 1:5,000
concentration and 2° anti-rabbit IgG at a 1:10,000 concentration. All samples were
produced and tested according to the developed screening method protocol as
described in materials and methods section.
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plasmid in this system is sufficient for demonstration of correct substrate specificity of
these model PTKs toward their respective substrates. Once substrate specificity of
Abl, Csk and Src toward their known substrates was demonstrated using this system,
the next step was to validate the system further using both mutant PTKs and mutated
substrates.

Testing of mutant PTKs to further validate system
The next step to further validate the developed method to analyze PTKs for
substrate specificity was to test two specific mutant PTKs generated; Csk R281A, +
R283A and Src RSRGRS+ K458F. Both of these mutants have had amino acids
mutated which have previously been shown to have altered phosphorylation activity
on the substrate kdSrc when compared to their wild-type forms.(6)
The first mutant PTK tested, Csk double mutant (DM) R281A + R283A, has had
arginine residues replaced with alanine residues at amino acids 281 and 283. This has
been shown in vitro, using radioactive kinase assays, to cause this mutant to
dramatically lose its ability to phosphorylate kdSrc at its inactivation site, tyrosine
residue 527, when compared to wild type Csk.[6] Therefore, it is expected, once tested
using the proposed screening method, that this mutant should demonstrate a loss of
phosphorylation activity on kdSrc at tyrosine residue 527, when compared to wild
type.
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In fact, this is what was observed as shown in Figure 4. Once this Csk R281A +
R283A mutant demonstrated the expected phosphorylation activity when tested, the
next mutant analyzed in this system was Src RSRGRS + K458F.
The Src RSRGRS + K458F mutant has had amino acids 354-359 (KGETGK)
replaced with the amino acid sequence RSRGRS as well as a K458F mutation. These
seven residues are collectively referred to as the substrate-docking site of Csk and
have been shown to be crucial for Csk phosphorylation of Src at tyrosine residue
527.[6] To figure out which amino acids of Src to replace with the residues crucial for
Csk’s recognition of Src at tyrosine residue 527 (RSRGRS), a sequence alignment was
performed between Csk and Src’s peptide binding lobe (figure 5). Once determined
which amino acids to mutate, this specific Src mutant was made and tested, in vitro;
showing much higher phosphorylation activity at tyrosine residue 527 of kdSrc when
compared to wild type Src, which phosphorylates this residue minimally.(6) Therefore,
this altered phosphorylation activity should be demonstrated when tested in this in
vivo optimized system to further establish its accuracy. It was shown that this Src
mutant does indeed phosphorylate substrate kdSrc on tyrosine residue 527 at a much
greater level when compared to wild type form as seen in Figure 6.
To show that the Src RSRGRS +K458F, mutant still retained its auto-phosphorylation
ability at tyrosine residue 416 of kdSrc despites the mutations, a western blot was
performed using antibodies specific for this residue. As seen in Figure 7 below, this
mutant still retained its phosphorylation activity at tyrosine residue 416 of kdSrc,
although it is less active, when compared to Src (wt).
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kdSrc

Figure 4. Csk (wt) vs. Csk (DM) R281A + R283A, phosphorylation of substrate
kdSrc at tyrosine residue 527. All samples tested contained an identical substrate,
kdSrc. Lane 1 serves as a control containing substrate kdSrc only with no PTK coexpression. Lanes 2 and 4 contain the substrate kdSrc co-expressed with either Csk
(wt) or Csk (DM) R281A + R283A. The approximate kdSrc band is indicated by the
arrow. Antibodies used to perform blot were 1° Phospho-Src (Y527) at a 1:5,000
concentration and 2° anti-rabbit IgG at a 1:10,000 concentration. All samples were
produced and tested according to the developed screening method protocol as
described in materials and methods section.
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Figure 5. Alignment of the amino acid sequences of Csk, Chk, Src, and Hck in the
peptide-binding lobe.
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Figure 5. Alignment of the amino acid sequences of Csk, Chk, Src, and Hck in the
peptide-binding lobe. Residues that are uniquely conserved in the Csk family are
highlighted blue (polar or charged) or red (hydrophobic or Gly). Figure adapted from
Lee et al. [6]
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Figure 6. Src (wt) vs. Src (DM) RSRGRS + K458F phosphorylation activity of
substrate kdSrc at tyrosine residue 527. All samples tested contained an identical
substrate, kdSrc. Lane 1 serves as a control containing substrate kdSrc only and no
PTK co-expression. Lane 2 and 4 represent both wild type and mutant Csk and Src
PTKs co-expressed separately with substrate kdSrc. The approximate kdSrc band is
indicated by the arrow. Antibodies used to perform blot were 1° Phospho-Src (Y527)
at a 1:5,000 concentration and 2° anti-rabbit IgG at a 1:10,000 concentration. All
samples were produced and tested according to the developed screening method
protocol as described in materials and methods section.
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Figure 7. Src (wt) vs. Src (DM) RSRGRS + K458F phosphorylation activity of
substrate kdSrc at tyrosine residue 416. All samples tested contained an identical
substrate, kdSrc. Lane 1 serves as a control containing substrate kdSrc only and no
PTK co-expression. Lane 2 and 4 represent both wild type and mutant Csk and Src
PTKs co-expressed separately with substrate kdSrc. The approximate kdSrc band is
indicated by the arrow. Antibodies used to perform blot were 1° Phospho-Src (Y527)
at a 1:5,000 concentration and 2° anti-rabbit IgG at a 1:10,000 concentration. All
samples were produced and tested according to the developed screening method
protocol as described in materials and methods section.
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Testing of mutant substrates
The final step to validating the established system for screening PTKs for
substrate specificity was to test two specific mutants of substrate kdSrc. The first
mutant, kdSrc Y416F, has had the autophosphorylation tyrosine residue 416 replaced
with a phenylalanine residue. The purpose of this generated mutation was to greatly
reduce autophosphorylation by Src PTKs on this specific residue. In fact, this mutant
did demonstrate a much lower level of phosphorylation activity by Src at this residue
when tested in vitro. The second mutant, kdSrc Y527F, has the tyrosine 527 crucial for
its inactivation replaced with a phenylalanine residue. In consequence, in vitro assays
demonstrated a much lower level of phosphorylation by Csk on this altered residue
then when compared versus kdSrc. Therefore, these two specific mutants of kdSrc
were chosen as good candidates to validate the developed system.
The first mutant tested, kdSrc Y416F, should demonstrate a greatly reduced
phosphorylation activity by Src at tyrosine residue 416 when compared with Src
activity on kdSrc. As expected, when tested, the kdSrc Y416F mutant showed reduced
levels of phosphorylation by Src compared to kdSrc. Having tyrosine residue 416
replaced with a phenylalanine greatly reduced Src’s ability to phosphorylate this
generated mutant as seen in Figure 8 below.
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FIGURE 8. Csk and Src phosphorylation of kdSrc vs kdSrc (Y416F) substrates on
tyrosine residue 416. Lane 1 represents a control with substrate kdSrc (Y416) only
without co-expression of PTK. Lanes 2 and 4 represent Csk and Src co-expressed
separately with kdSrc. Lanes 3 and 5 represent Csk and Src co-expressed separately
with mutant substrate kdSrc (Y416F). The approximate kdSrc band is indicated by the
arrow. Antibodies used to perform blot were 1° Phospho-Src (Y416) at a 1:5,000
concentration and 2° anti-rabbit IgG at a 1:10,000 concentration. All samples were
produced and tested according to the developed screening method protocol as
described in materials and methods section.
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The second mutant tested within this developed system was kdSrc (Y527F), a
mutant lacking the crucial tyrosine necessary for its inactivation at this site. As
expected, when co-expressed with Csk, the kdSrc (Y527F) mutant substrate
demonstrated a greatly reduced phosphorylation level at tyrosine 527 when compared
to kdSrc in the same setup, as shown in figure 9. This is a further indication of the
effectiveness of the optimized method for analyzing substrate specificity in PTKs.

Optimization of developed colony screening method
Initially, the first attempt when establishing the colony screening method was
to use the strains to be tested directly from an isolation streak plate with isolated
colonies. These individual colonies were aseptically spotted with toothpicks directly
onto nitrocellulose membranes, and these membranes were placed in a petri dish
containing 20ml 0.4mM IPTG for 1 hour to promote induction of cells contained on
membranes. Following this, membranes were transferred to another petri dish
containing approximately 15ml of 10% SDS and heated in a 95°C oven for 10
minutes, to promote lysing of cells and release of proteins to be blotted. After lysing,
membranes were dried and blotted using the optimized western blot protocol described
in the materials and methods section.
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FIGURE 9. Csk and Src phosphorylation of kdSrc vs KdSrc (Y527F) substrates on
tyrosine residue 527. Lane 1 represents a control with substrate kdSrc (Y527F) only
without co-expression of PTK. Lanes 2 and 4 represent Csk and Src co-expressed
separately with kdSrc. Lanes 3 and 5 represent Csk and Src co-expressed separately
with mutant substrate kdSrc (Y527F). The approximate kdSrc band is indicated by the
arrow. Antibodies used to perform blot were 1° Phospho-Src (Y527) at a 1:5,000
concentration and 2° anti-rabbit IgG at a 1:10,000 concentration. All samples were
produced and tested according to the developed screening method protocol as
described in materials and methods section.
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Using this method, the three strains containing Abl, Csk and Src co-expressed
individually with crk-l substrate were used to prepare a membrane as shown in figure
10a. Once prepared, the membrane was blotted using the Phospho-crk-l (Tyr207)
antibody which detects phosphorylation on tyrosine residue 207 of crk-l, Abl’s
preferred substrate. In contrast, Src minimally phosphorylates this residue while Csk
has not been shown to act on this residue. Once the prepared membrane was blotted,
Abl did display a much higher phosphorylation activity when compared to both Csk
and Src as shown in figure 10b.
Although the correct substrate specificity was demonstrated with the protocol
used to generate samples used in figure 10b, the signals tended to overlay and transfer
to other sections of the membrane while exposing films. Therefore, double sets of
identical signals would be observed either below or above where the colonies were
toothpicked onto the membrane. Another issue with this protocol was that colonies
would wash off occasionally during the induction and lysing process and therefore, no
signal would be observed. In an effort to overcome this, the protocol was altered so
that the strains tested were to be grown and induced in liquid culture, rather than
grown on an LB plate and induced on the sample-containing membrane as used to
generate samples in figure 10b. Samples would then be pipetted directly onto them
membrane, lysed and blotted. This optimization was done in hopes to limit the
problems of transferred colonies washing off the membrane, or signals being
transferred over to nearby sections of membrane.
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Figure 10. Optimization of colony screening method by testing substrate specificity of
PTKs Abl, Csk and Src at tyrosine residue 207 of crk-l substrate. A. Shown is the
setup of colonies transferred directly onto a nitrocellulose membrane to be tested and
blotted. All samples tested contained a similar crk-l substrate. B. Either of three PTKs
Abl, Csk and Src was co-expressed with substrate crk-l and 5 samples of each were
toothpicked as indicated in figure. After induction and lysing, membrane was blotted
with primary antibody Phospho-crk-l (tyr207) at a concentration of 1:50,000 and
secondary anti-mouse IgG at a 1:15,000 concentration.
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Although the prior protocol did demonstrate the ability to screen PTKs for substrate
specificity when phosphorylation activity of PTKs Abl, Csk, and Src was tested at
tyrosine residue 207 of crk-l substrate, its optimization did indeed lead to better and
cleaner results.

Use of optimized sample preparation protocol for colony screening substrate
specificity of kdSrc
To optimize this colony screening protocol, along with changes to sample and
membrane preparation, it was concluded that growing the colonies in liquid culture
and then pipetting calculated volumes of these cultures directly onto the membrane
would remove some of the setbacks of the prior protocol. To determine appropriate
volume of sample to be pipetted onto the nitrocellulose membrane, several test runs
had to be performed. Initially, 1µl of sample tested was spotted directly onto the
membrane. Although this seems like a small amount of sample, it was determined that
this amount used was actually causing the samples tested to produce results that are
not indicative of the expected substrate specificity. For example, when testing
phosphorylation activity of kdSrc substrate at tyrosine residue 416 by PTKs Abl, Csk
and Src, both Abl and Src were showing similar phosphorylation activity on this
residue, contrary to expected. This blot is shown below in Figure 11. Therefore, the
amount of each culture pipetted directly onto the membrane was reduced to
approximately 0.5µl. At this low volume, samples were shown to demonstrate proper
substrate specificity.
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Figure 11. Phosphorylation activity of PTKs Abl, Csk, and Src at tyrosine residue
416 of substrate kdSrc using an optimized protocol. All PTKs tested were cotransformed with the same kdSrc substrate. Amount of samples pipetted onto
membrane and blotted was 1µl per spot. Either of three PTKs Abl, Csk and Src was
co-expressed with substrate kdSrc and 5 samples of each were spotted as indicated in
figure 2. The final set of samples (bottom row) were substrate kdSrc samples with no
PTK co-expression used as a control (autophosphorylation). Membrane was blotted
with primary antibody Phospho-Src (Tyr416) at a 1:5,000 concentration and secondary
anti-rabbit IgG antibody at a 1:10,000 concentration.
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Once this appropriate sample volume was established, a membrane was setup to
demonstrate substrate specificity of PTKs Abl, Csk and Src at tyrosine residue 416 of
substrate kdSrc. If proper substrate specificity is observed using this new protocol,
then Src when co-expressed with kdSrc should show the greatest phosphorylation
activity on tyrosine residue 416 when compared to both Abl and Csk co-expressed
with similar substrate. In fact, this is what was demonstrated as shown in figure 11
below.
As Figure 12 demonstrates, proper substrate specificity by the tested PTKs was
achieved in relation to phosphorylation activity at tyrosine residue 416 using this
lesser volume of sample. Therefore, this identical 0.5µl sample volume was used in
the last blot due to its success.
Upon establishing the expected substrate specificity of PTKs Abl, Csk and Src toward
substrate kdSrc on tyrosine residue 416, the next step was to test for phosphorylation
activity on tyrosine residue 527 of kdSrc by these same three enzymes. If this method
is accurate, Csk should demonstrate high phosphorylation activity on tyrosine residue
527 of kdSrc when compared to both Abl and Src which have demonstrated minimal
activity at this site. Once tested using the developed protocol, the expected result was
observed and can be seen in figure 13.
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Figure 12. Phosphorylation activity of PTKs Abl, Csk, and Src at tyrosine residue 416
of substrate kdSrc using lesser volume of sample. All PTKs tested were cotransformed with the same kdSrc substrate. Amount of samples pipetted onto
membrane and blotted was 0.5µl per spot. Either of three PTKs Abl, Csk and Src was
co-expressed with substrate kdSrc and 5 samples of each were spotted as indicated in
Figure 10. The final set of samples (top row) contains substrate kdSrc with no PTK
co-expression as a control. Membrane was blotted with primary antibody Phospho-Src
(Tyr416) at a 1:5,000 concentration and secondary anti-rabbit IgG antibody at a
1:10,000 concentration. Blot was carried out by Yixin Cui.
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Figure 13. Phosphorylation activity of PTKs Abl, Csk, and Src at tyrosine residue 527
of substrate kdSrc using lesser volume of sample. All samples tested contained similar
kdSrc substrate. Amount of samples pipetted onto membrane and blotted was 0.5µl
per spot. Either of three PTKs Abl, Csk and Src was co-expressed with substrate kdSrc
and 5 samples of each were spotted as indicated in figure 9a. The final set of samples
(bottom row) contains substrate kdSrc with no PTK co-expression as control.
Membrane was blotted with primary antibody Phospho-Src (Tyr527) at a 1:5,000
concentration and secondary anti-rabbit IgG antibody at a 1:10,000 concentration.
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Discussion
Overall, the goal when developing this novel system to screen PTKs for
substrate specificity was to first optimize the protocol to make it very easy to screen
for substrate specificity when testing different PTKs. The second goal was to use
model PTKs Abl, Csk and Src along with a few of their preferred substrates to
demonstrate the effectiveness of using this system to screen PTKs for substrate
specificity. Finally, the third goal was to use a set of generated mutant PTKs and
mutant substrates in an effort to further verify that this system can screen PTKs for
substrate specificity, even mutant samples.
Initially, several optimizations were made in an effort to demonstrate the proper
expected substrate specificity. First, it was determined that cultures used to produce
cell lysates in the system had to be grown to a specific OD600 value generally between
0.7-1.2(logarithmic phase). If cultures were grown too little, the signals produced by
western blot were hard to detect, and if the cultures are grown too much, the substrates
tested would generally become too phosphorylated regardless of which PTK was
tested. Therefore if cultures are grown to an OD600 value that is too high, and testing
of substrate kdSrc on tyrosine 416 is performed with different PTKs, both Csk and Src
would both show high phosphorylation activity on the substrate tested even though
Csk phosphorylates this residue minimally. Therefore, growth of the cultures must be
limited to the logarithmic phase OD600 value.
Another optimization made was in choosing which plasmids to use for expression of
the genes of substrates and PTKs tested. Initially the genes of substrates were cloned
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into low-copy number plasmid pCDF-1b and genes of PTKs into high-copy number
plasmids pRSET-A or pGEX-4t-1 as carried out by Yixin Cui. After further testing,
this proved to be unsuccessful. The reason for this is that if the amount of substrate
expressed is limited compared to the amount of PTK expressed, substrate specificity
of any PTK tested with a specific substrate will generally be masked. For example, if
100 substrate kdSrc proteins are produced and 1000 Csk and Src PTKs are each
produced, and these samples are tested and blotted for phosphorylation of kdSrc at
tyrosine residue 416, then a difference in substrate specificity will not be seen. The
researcher will observe that kdSrc at tyrosine residue 416 has been phosphorylated
equally by both Csk and Src even though this is not what occurs in nature. Therefore,
to overcome this problem, the genes of the substrates tested were cloned and
expressed in high-copy number plasmids pRSET-A (kdSrc) or pGEX-4t-1(crk-l) and
genes of PTKs in low-copy number plasmid pCDF-1b. By limiting the amount of
PTKs expressed in contrast to the number of substrate being produced, proper
difference in substrate specificity could be observed and achieved with this developed
system. These were the two biggest optimizations made to the developed system in an
effort to make it as accurate as possible when analyzing substrate specificity. The
second goal of this research was to use this optimized system in combination with
testing three important PTKs Abl, Csk and Src along with two substrates, crk-l and
kdSrc, in an effort to demonstrate that it can achieve proper substrate specificity. With
the optimizations made, the results seen did indeed show that the system could
demonstrate a difference in substrate specificity by different PTKs when tested against
chosen substrates.
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The first important result demonstrated was when testing phosphorylation activity at
tyrosine residue 207 of substrate crk-l when co-expressed individually with Abl, Csk
and Src. Since crk-l is one of Abl’s preferred substrates and is minimally
phosphorylated by both Csk and Src, this difference in substrate specificity should be
and was demonstrated by this system. The second result was testing phosphorylation
activity of kdSrc at tyrosine residue 416 when co-expressed individually with the same
three PTKs as above. Since Src phosphorylates this residue heavily in comparison to
both Abl and Csk, this should be demonstrated when tested using the developed
system. When tested, this expected result was produced and repeated. Finally,
phosphorylation activity of kdSrc at tyrosine 527 by Abl, Csk and Src was tested using
this optimized system. Csk shows much greater phosphorylation activity at this
residue when compared to Abl and Src. It was indeed shown that Csk phosphorylation
activity on tyrosine residue 527 on kdSrc was much greater in comparison to the Abl
and Src as expected. Once substrate specificity was demonstrated using the three
chosen model PTKs Abl, Csk, and Src, the final step taken was to validate the use of
this developed method with mutant PTKs and substrates.
The first mutant tested, Csk (DM) R281A + R283A, has specific amino acids
arginine residues replaced with alanine in its peptide binding lobe region. These
residues, when mutated, cause a dramatic loss in this mutant’s phosphorylation
activity on tyrosine residue 527 of kdSrc.[6] When tested using the developed system,
this loss of activity on tyrosine 527 of kdSrc was demonstrated and highly reduced
when compared to Csk’s (wt) activity on this same substrate.
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The second mutant tested, Src RSRGRS +K458F, has had amino acids 354-359
(KGETGK) replaced with RSRGRS amino acid sequence and a K458F replacement,
giving this mutant the ability to phosphorylate kdSrc substrate on tyrosine residue
527.[6] This mutant should demonstrate this altered phosphorylation activity when
implemented in the developed system if the system is to be further validated. It was
shown that the Src RSRGRS + K458F mutant phosphorylated kdSrc on tyrosine
residue 527 much more when compared to Src (wt)’s activity on this residue as
expected. Once this was accomplished, the final validation for this developed method
was to test two specific mutant substrates, kdSrc (Y416F) and kdSrc (Y527F). The
first mutant, kdSrc (Y416F) has had the tyrosine residue at its auto-phosphorylation
site replaced with a phenylalanine residue. The result of this mutation is that this site
can no longer be phosphorylated by PTKs and therefore this should be demonstrated
when tested using the method developed to screen PTKs for substrate specificity.
Once tested, the kdSrc (Y416F) mutant when co-expressed with either Csk or Src
shows little to no phosphorylation activity. In contrast, kdSrc (wt) is phosphorylated
heavily by Src as shown by testing. Finally, mutant kdSrc (Y527F) which has had the
tyrosine residue 527 at its inactivation site replaced with a phenylalanine residue
should demonstrate a lack of phosphorylation activity by both Csk and Src when
tested on this residue. As expected, Csk which heavily phosphorylates kdSrc (wt) on
tyrosine 527 showed a lack of phosphorylation activity when co-expressed with kdSrc
(Y527F) in this system. Src which minimally phosphorylated kdSrc(wt) at tyrosine
residue 527 also showed a loss of activity when co-expressed with this mutant.
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Overall, after optimization and testing of both wild type and mutant PTKs/substrates
using this developed system, its effectiveness at displaying substrate specificity of
different wild type and mutant model PTKs and substrates was demonstrated through
repeated testing. Concluding, there are many beneficial reasons to use this developed
method to screen protein tyrosine kinases for substrate specificity. For one, it negates
most of the drawbacks that other in vivo and in vitro methods used for analyzing PTK
substrate specificity, present. Second to this, once setup of system is established,
results can be produced within 1-2 days, which is rapid compared to other methods.
Finally, with the established protocol, using this system is fairly convenient and
employs basic laboratory techniques in which any researcher can execute.
Once the method above was established in being effective for screening PTKs
for substrate specificity, the protocol was optimized to allow a researcher to rapidly
screen a large number of PTK mutants generated through current techniques such as
DNA shuffling.[7,8] After a few changes, a developed colony screening method for
rapidly screening PTKs was established and proven effective by using model PTKs
Abl, Csk and Src and the preferred substrates. Although no mutant PTKs were tested
during this study, by demonstrating the proper substrate specificity of model PTKs,
the goal was to provide convincing evidence that this method can be used to screen
mutant PTKs that can be generated through DNA shuffling or other methods.
Concluding, this novel colony screening method provides a rapid way to screen
mutant PTKs, once generated, for chosen substrate specificity in a cost-effective,
replicative manner.
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One drawback of both systems is that the observed specificity is not quantitative and
thus once substrate specificity is demonstrated using either method, it needs to be
further quantified by other methods, such as radioactive analysis.
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